(Q44362904)

English

Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival

scientific article published on 22 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

based on heuristic

inferred from title

6

object named as

Patrick Y Wen

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Alona Muzikansky

4

object named as

Alona Muzikansky

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

author name string

Christina Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Raymond Huang

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Ainsley MacLean

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Srinivasan Mukundan

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Andrew D Norden

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

22 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

115

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

267-276

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

https://scigraph.springernature.com/pub.10.1007/s11060-013-1225-0

0 references

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Advances in MRI assessment of gliomas and response to anti-VEGF therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Prediction of glioblastoma multiform response to bevacizumab treatment using multi-parametric MRI.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Diffusion-weighted imaging with calculated apparent diffusion coefficient of enhancing extra-axial masses.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Apparent diffusion coefficient of human brain tumors at MR imaging

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Minimum apparent diffusion coefficients in the evaluation of brain tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974656

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Apparent diffusion coefficients for differentiation of cerebellar tumors in children.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974656

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974656

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-013-1225-0

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44362904&oldid=2020081749"